Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations

被引:3
|
作者
V. Faino, Anna [1 ,4 ]
Hoffman, Lucas R. [2 ]
Gibson, Ronald L. [2 ]
Kronman, Matthew P. [3 ]
Nichols, David P. [2 ]
Rosenfeld, Margaret [2 ]
Cogen, Jonathan D. [2 ]
机构
[1] Seattle Childrens Res Inst, Core Biostat Epidemiol & Analyt Res, Seattle, WA USA
[2] Univ Washington, Dept Pediat, Div Pulm & Sleep Med, Seattle, WA USA
[3] Univ Washington, Seattle Childrens Hosp, Div Infect Dis, Dept Pediat, Seattle, WA USA
[4] Seattle Childrens Res Inst, 1920 Terry Ave,Mail Stop CURE 4, Seattle, WA 98101 USA
关键词
OROPHARYNGEAL CULTURES; THERAPY; INFANTS;
D O I
10.1016/j.jcf.2023.02.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: No data exist to guide antibiotic selection among people with CF (PwCF) with respiratory cultures positive for multiple CF-related bacteria (polymicrobial infections). This study aimed to describe the number of polymicrobial in-hospital treated pulmonary exacerbations (PEx), to determine the proportion of polymicrobial PEx where antibiotics were prescribed with activity against all bacteria detected (termed complete antibiotic coverage), and to determine clinical and demographic factors associated with complete antibiotic coverage.Methods: Retrospective cohort study using the CF Foundation Patient Registry-Pediatric Health Information System dataset. Children aged 1-21 years with an in-hospital treated PEx from 2006 to 2019 were eligible for inclusion. Bacterial culture positivity was based on any positive respiratory culture in the 12 months prior to a study PEx. Results: A total of 4,923 children contributed 27,669 total PEx of which 20,214 were polymicrobial; of these, 68% of PEx had complete antibiotic coverage. In regression modeling, a prior PEx with complete antibiotic coverage for MRSA was associated with a higher likelihood of having complete antibiotic coverage at a subsequent study PEx (OR (95% CI) 3.48 (2.50, 4.83)).Conclusions: The majority of children with CF hospitalized for polymicrobial PEx were prescribed complete antibiotic coverage. Prior PEx treatment with complete antibiotic coverage predicted complete antibiotic coverage at a future PEx for all bacteria studied. Studies are needed comparing outcomes of polymicrobial PEx treated with different antibiotic coverages to optimize PEx antibiotic selection.(c) 2023 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:630 / 635
页数:6
相关论文
共 50 条
  • [1] PROLONGATION OF ANTIBIOTIC TREATMENT FOR CYSTIC FIBROSIS PULMONARY EXACERBATIONS
    Waters, V. J.
    Stanojevic, S.
    Klingel, M.
    Chiang, J.
    Sonneveld, N.
    Kukkar, R.
    Tullis, E.
    Ratjen, F.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 351 - 351
  • [2] Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations
    Waters, Valerie
    Stanojevic, Sanja
    Klingel, Michelle
    Chiang, Jackie
    Sonneveld, Nicole
    Kukkar, Richa
    Tullis, Elizabeth
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 770 - 776
  • [3] Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations
    Montemayor, Kristina
    Psoter, Kevin J.
    Lechtzin, Noah
    Carson, Sara W.
    Merlo, Christian A.
    Dezube, Rebecca H.
    Riekert, Kristin A.
    Allgood, Sarah
    Toporek, Alexandra
    Jennings, Mark T.
    West, Natalie E.
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (06) : 920 - 925
  • [4] Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis
    Daniels, T. W. V.
    Rogers, G. B.
    Stressmann, F. A.
    van der Gast, C. J.
    Bruce, K. D.
    Jones, G. R.
    Connett, G. J.
    Legg, J. P.
    Carroll, M. P.
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (01) : 22 - 28
  • [5] The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations
    Zikic, Andrew
    Ratjen, Felix
    Shaw, Michelle
    Tullis, Elizabeth
    Waters, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (05) : 759 - 765
  • [6] PREDICTORS OF RESPONSE TO ANTIBIOTIC TREATMENT OF PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS PATIENTS
    Ratjen, F.
    Stanojevic, S.
    Sonneveld, N.
    Grasemann, H.
    Yau, Y.
    Tullis, E.
    Wilcox, P. G.
    Freitag, A.
    Chilvers, M.
    Waters, V. J.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 355 - 355
  • [7] OUTCOMES OF ORAL ANTIBIOTIC TREATMENT FOR PULMONARY EXACERBATIONS IN CHILDREN WITH CYSTIC FIBROSIS
    Hoppe, J.
    Colborg, A.
    Hinds, D.
    Wagner, B.
    Morgan, W. J.
    Rosenfeld, M.
    Zemanick, E. T.
    Sanders, D. B.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S423 - S423
  • [8] Treatment of pulmonary exacerbations in cystic fibrosis
    Bhatt, Jayesh M.
    EUROPEAN RESPIRATORY REVIEW, 2013, 22 (129): : 205 - 216
  • [9] Treatment of pulmonary exacerbations in cystic fibrosis
    Ng, Christabella
    Nadig, Tejaswi
    Smyth, Alan R.
    Flume, Patrick
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (06) : 679 - 684
  • [10] Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
    Flume, Patrick A.
    Mogayzel, Peter J., Jr.
    Robinson, Karen A.
    Goss, Christopher H.
    Rosenblatt, Randall L.
    Kuhn, Robert J.
    Marshall, Bruce C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (09) : 802 - 808